Drug Profile
GSK 1795091
Alternative Names: GSK1795091Latest Information Update: 07 Jun 2022
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antineoplastics
- Mechanism of Action Immunomodulators; Toll-like receptor 4 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Head and neck cancer; Solid tumours
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in Canada (IV, Injection)
- 28 May 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in Netherlands (IV, Injection)
- 28 May 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain (IV, Injection)